article Open AccessTop 1% cited

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Breast Cancer Research and Treatment · 2017 · Vol. 167(3) · pp. 671–686

Luc Dirix✉(University of Antwerp)István Takács(Semmelweis University)Guy Jérusalem(University of Liège)Petros Nikolinakos(University Cancer and Blood Center)Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute)Andres Forero‐Torres(University of Alabama at Birmingham)Ralph V. Boccia(Center for Cancer and Blood Disorders)Marc E. Lippman(University of Miami)Robert A. Somer(Cooper University Hospital)Martin ŠmakalLeisha A. Emens(Johns Hopkins University)Borys Hrinczenko(Michigan State University)W. Jeff Edenfield(Prisma Health)Jayne S. Gurtler(Littoral Research Group (United States))Anja von Heydebreck(Merck (Germany))H. Grote(Merck (Germany))Kevin M. Chin(Ono Pharmaceutical (United States))Erika Hamilton(Sarah Cannon)

View via DOI Full-text PDF

Abstract

Avelumab showed an acceptable safety profile and clinical activity in a subset of patients with MBC. PD-L1 expression in tumor-associated immune cells may be associated with a higher probability of clinical response to avelumab in MBC.

Cancer Immunotherapy and Biomarkers Cancer Cells and Metastasis Colorectal Cancer Treatments and StudiesJavelinAvelumabMedicineBreast cancerMetastatic breast cancerAntibodyOncologyCancerInternal medicineMammary gland

MeSH terms

AdultAgedAntibodies, Anti-IdiotypicAntibodies, MonoclonalFemaleHumansMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalGene Expression Regulation, NeoplasticDisease-Free SurvivalB7-H1 AntigenAntibodies, Monoclonal, HumanizedTriple Negative Breast Neoplasms